Montag A & Associates Inc. Decreases Stock Holdings in IQVIA Holdings Inc. (NYSE:IQV)

Montag A & Associates Inc. lessened its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 31.0% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 17,031 shares of the medical research company's stock after selling 7,638 shares during the quarter. Montag A & Associates Inc.'s holdings in IQVIA were worth $3,347,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. Capital Performance Advisors LLP bought a new position in IQVIA in the third quarter worth $27,000. Avior Wealth Management LLC grew its stake in shares of IQVIA by 117.6% in the third quarter. Avior Wealth Management LLC now owns 161 shares of the medical research company's stock worth $38,000 after acquiring an additional 87 shares during the last quarter. Synergy Asset Management LLC purchased a new stake in shares of IQVIA in the fourth quarter worth $33,000. Assetmark Inc. grew its stake in shares of IQVIA by 612.5% in the third quarter. Assetmark Inc. now owns 228 shares of the medical research company's stock worth $54,000 after acquiring an additional 196 shares during the last quarter. Finally, Concord Wealth Partners purchased a new stake in shares of IQVIA in the third quarter worth $57,000. Institutional investors own 89.62% of the company's stock.

IQVIA Stock Performance

Shares of IQVIA stock traded up $3.39 during trading hours on Wednesday, reaching $196.54. 1,702,945 shares of the stock traded hands, compared to its average volume of 1,412,729. The company has a 50 day moving average price of $199.95 and a 200 day moving average price of $217.09. The firm has a market capitalization of $34.61 billion, a price-to-earnings ratio of 26.21, a P/E/G ratio of 1.98 and a beta of 1.48. The company has a quick ratio of 0.84, a current ratio of 0.84 and a debt-to-equity ratio of 2.12. IQVIA Holdings Inc. has a one year low of $187.62 and a one year high of $261.73.

IQVIA (NYSE:IQV - Get Free Report) last announced its quarterly earnings data on Thursday, February 6th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $3.11 by ($0.21). IQVIA had a net margin of 8.91% and a return on equity of 28.81%. On average, equities research analysts expect that IQVIA Holdings Inc. will post 10.86 earnings per share for the current fiscal year.

Insider Buying and Selling

In other IQVIA news, Director John G. Danhakl purchased 1,275 shares of the stock in a transaction that occurred on Tuesday, December 3rd. The shares were bought at an average cost of $200.58 per share, with a total value of $255,739.50. Following the acquisition, the director now owns 1,275 shares in the company, valued at approximately $255,739.50. This trade represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 1.60% of the stock is owned by insiders.

Analysts Set New Price Targets

A number of research firms have recently commented on IQV. Barclays cut their target price on IQVIA from $255.00 to $235.00 and set an "overweight" rating on the stock in a research note on Monday, February 3rd. Robert W. Baird reduced their price objective on IQVIA from $212.00 to $210.00 and set a "neutral" rating for the company in a report on Tuesday, January 21st. Stifel Nicolaus reduced their price objective on IQVIA from $273.00 to $261.00 and set a "buy" rating for the company in a report on Friday, February 7th. Royal Bank of Canada reiterated an "outperform" rating and issued a $270.00 price objective on shares of IQVIA in a report on Monday, February 10th. Finally, StockNews.com downgraded IQVIA from a "buy" rating to a "hold" rating in a report on Thursday, November 28th. Four analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat, IQVIA has an average rating of "Moderate Buy" and an average price target of $251.22.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.